Biomarkers of Cellular Senescence and Aging: Current State-of-the-Art, Challenges and Future Perspectives


Author: Subramanian Muthamil1, Hyun-Yong Kim1, Hyun-Jun Jang1, Ji-Hyo Lyu1, Ung Cheol Shin1, Younghoon Go2, Seong-Hoon Park3, Hee Gu Lee4, Jun Hong Park1,5

Affiliation: <sup>1</sup> Herbal Medicine Resources Research Center, Korea Institute of Oriental Medicine, Jeollanam-do, Naju, 58245, Republic of Korea.

<sup>2</sup> Korean Medicine (KM)-application Center, Korea Institute of Oriental Medicine, Daegu, 41062, Republic of Korea.

<sup>3</sup> Genetic and Epigenetic Toxicology Research Group, Korea Institute of Toxicology, Daejeon, 34114, Republic of Korea.

<sup>4</sup> Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea.

<sup>5</sup> Korean Convergence Medicine Major, University of Science & Technology (UST), KIOM Campus, Daejeon, 34054, Republic of Korea.
Conference/Journal: Adv Biol (Weinh)
Date published: 2024 Jun 27
Other:
  Pages: e2400079   ,  Special Notes: doi: 10.1002/adbi.202400079.   ,  Word Count: 199  
    Population aging has increased the global prevalence of aging-related diseases, including cancer, sarcopenia, neurological disease, arthritis, and heart disease. Understanding aging, a fundamental biological process, has led to breakthroughs in several fields. Cellular senescence, evinced by flattened cell bodies, vacuole formation, and cytoplasmic granules, ubiquitously plays crucial roles in tissue remodeling, embryogenesis, and wound repair as well as in cancer therapy and aging. The lack of universal biomarkers for detecting and quantifying senescent cells, in vitro and in vivo, constitutes a major limitation. The applications and limitations of major senescence biomarkers, including senescence-associated β-galactosidase staining, telomere shortening, cell-cycle arrest, DNA methylation, and senescence-associated secreted phenotypes are discussed. Furthermore, explore senotherapeutic approaches for aging-associated diseases and cancer. In addition to the conventional biomarkers, this review highlighted the in vitro, in vivo, and disease models used for aging studies. Further, technologies from the current decade including multi-omics and computational methods used in the fields of senescence and aging are also discussed in this review. Understanding aging-associated biological processes by using cellular senescence biomarkers can enable therapeutic innovation and interventions to improve the quality of life of older adults.



Keywords: SASPs; SA‐β‐gal; aging; multi‐omics; organoids; senescence; senotherapeutics.



PMID: 38935557 DOI: 10.1002/adbi.202400079